Key clinical point: Relugolix, an oral gonadotropin-releasing hormone antagonist, was effective at suppressing testosterone levels over 48 weeks.
Major finding: At 48 weeks, 96.7% of men on relugolix and 88.8% on leuprolide had sustained testosterone suppression (P < .001).
Study details: Phase 3 trial of 930 men with advanced prostate cancer.
Disclosures: The study was supported by Myovant. Dr. Shore disclosed relationships with Myovant and other companies.
Shore ND et al. ASCO 2020, Abstract 5602.